arrow
M

Michael C. Haffner

university of washington
H指数:51
被引数:9,598

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology

多组学评估揭示了LNCaP及其衍生细胞系在前列腺癌病理生物学中的决定因素

2025-11-170
OA
Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies

确定 aclarubicin 在儿科恶性肿瘤中的临床前安全性

2025-11-010
OAAI
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial

新辅助帕博利珠单抗联合加速甲氨蝶呤、长春碱、多柔比星和顺铂在非尿路上皮性肌层浸润性膀胱癌不同组织学亚型中的应用:一项II期临床试验

2025-08-050
PRE
Lossless Altered Histone Modification Analysis System (LAHMAS)

无损改变的组蛋白修饰分析系统

2025-07-270
PRE
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2025-02-070
PRE
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings

基于PET的TheraP资格及VISION试验合格患者中接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者的结局:18F-FDG显像不一致结果的重要性

2024-11-141
PRE
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
2024-09-170
OAAI
Single- cell analysis of treatment- resistant prostate cancer: Implications of cell state changes for cell surface antigen- targeted therapies
2024-07-054
OAAI
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
2024-05-173
OAAI
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2023-12-1814
OAAI
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer
2023-10-189
OA
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer
2023-10-018
OA